

1 From SARS and MERS to COVID-19: a review of the quality and
2 responsiveness of clinical management guidelines in outbreak
3 settings

4
5 Authors:

6 Samuel Lipworth* MBBS, Clinical Research Fellow 1,2

7 Ishmeala Rigby* MSc, Research Assistant 6

8 Vincent Cheng* DPhil, Senior Research Associate 4

9 Peter Bannister MSc, Medical Student 3

10 Eli Harriss BSc, Information Specialist 5

11 Karen Cook, BSc, Patient and Public Advocate 8

12 Erhui Cai, Postdoctoral Researcher 6

13 Mais Tattan MD, Postgraduate Student 3

14 Terrence Epie MD, Postgraduate Student 7

15 Lakshmi Manoharan MBBS, Research Assistant 6

16 Kate Lambe, MSc, Postgraduate Student 3

17 Melina Michelen MSc, Research Assistant 6

18 Anna Vila Gilibets, BSc, Medical Student 3

19 Andrew Dagens MRCP, Clinical Academic 6

20 Louise Sigfrid⁺ PhD, Clinical Research Fellow 6

21 Peter Horby⁺ FRCP, Professor 6

22

23 * Joint first authors

24 ⁺ Joint Senior authors

25

26 ¹ Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK

27 ² Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK

28 ³ Brighton and Sussex Medical School, Brighton, BN1 9PX, UK

29 ⁴ Bristol Medical School, University of Bristol, Bristol, BS8 1TL, UK

30 ⁵ Bodleian Health Care Libraries, University of Oxford, Oxford, OX3 9DU, UK

31 ⁶ International Severe Acute Respiratory and emerging Infection Consortium, Centre for

32 Tropical Medicine, University of Oxford, Oxford, OX3 7LG, UK

33 ⁷ University of Oxford, Oxford, OX3 2JD, UK

34 ⁸ Not applicable

35

36 Correspondence to: Louise Sigfrid, ISARIC GSC, Centre for Tropical Medicine and Global

37 Health, University of Oxford, Oxford, OX3 7LG, UK at Louise.Sigfrid@ndm.ox.ac.uk

38

39 Abstract

40 **Objective-** To assess the responsiveness and quality of clinical management guidelines

41 (CMGs) in SARS, MERS and COVID-19 and determine whether this has improved over time.

42 **Design-** Rapid literature review, quality assessment and focus group consultation.

43 **Data Sources** – Google and Google Scholar were systematically searched from inception to 6th

44 June 2020. This was supplemented with hand searches of national and international public

45 health agency and infectious disease society websites as well as directly approaching clinical

46 networks in regions where few CMGs had been identified via the primary search.

47 **Eligibility Criteria-** CMGs for the treatment of COVID-19/SARS/MERS providing

48 recommendations on supportive care and/or specific treatment.

49 **Methods-** Data extraction was performed using a standardised form. The Appraisal of
50 Guidelines for Research and Evaluation (AGREE-II) tool was used to evaluate the quality of the
51 CMGs. Six COVID-19 treatments were selected to assess the responsiveness of a subset of
52 guidelines and their updates to 20th November 2020. We ran two sessions of focus groups with
53 patient advocates to elicit their views on guideline development.

54 **Results-** We included 37 COVID-19, six SARS, and four MERS CMGs. Evidence appraisals in
55 CMGs generally focused on novel drugs rather than basic supportive care; where evidence for
56 the latter was provided it was generally of a low quality. Most CMGs had major methodological
57 flaws (only two MERS-CoV and four COVID-19 CMGs were recommended for use by both
58 reviewers without modification) and there was no evidence of improvement in quality over time.
59 CMGs scored lowest in the following AGREE-II domains: scope and purpose, editorial
60 independence, stakeholder engagement, and rigour of development. Of the COVID-19 CMGs,
61 only eight included specific guidance for the management of elderly patients and only ten for
62 high-risk groups; a further eight did not specify the target patient group at all. Early in the
63 pandemic, multiple guidelines recommended unproven treatments and whilst in general findings
64 of major clinical trials were eventually adopted, this was not universally the case. Eight
65 guidelines recommended that use of unproven agents should be considered on a case-by-case
66 basis. Patient representatives expressed concern about the lack of engagement with them in
67 CMG development and that these documents are not accessible to non-experts.

68 **Conclusion-** The quality of most CMGs produced in coronaviridae outbreaks is poor and we
69 have found no evidence of improvement over time, highlighting that current development
70 frameworks must be improved. There is an need to strengthen the evidence base surrounding
71 basic supportive care and develop methods to engage patients in CMG development from the
72 beginning in outbreak settings.

73 **Systematic review registration-** PROSPERO CRD42020167361

74

75

76 **Keywords**

77 Clinical Management Guidelines, Quality, Inclusivity, responsiveness, COVID-19, SARS,

78 MERS, AGREE-II

79 **Introduction**

80 Clinical management guidelines (CMGs) are useful tools to help clinicians provide quality,
81 evidence-based care to patients. Their utility is potentially even greater in an outbreak setting
82 when clinicians are faced with the challenges of managing a new pathogen combined with
83 increased pressures on healthcare services and redeployment to areas in which they have
84 limited experience. Outbreaks are however also associated with significant time pressure and
85 high levels of uncertainty, making production of methodologically rigorous guidelines difficult.¹

86

87 The SARS-CoV-2 pandemic has highlighted the disproportionate impact of infectious disease
88 outbreaks on vulnerable (e.g. the elderly and immunosuppressed)² and socioeconomically
89 disadvantaged groups in society.³ Infectious diseases often present differently in these
90 populations and yet most CMGs produced early in the pandemic did not provide specific advice
91 for the management of these groups.¹ As knowledge about new diseases increases as time
92 elapses, the inclusivity, quality and usefulness of CMGs should also improve. Pandemics such
93 as COVID-19 are likely to occur with increasing frequency throughout the 21st Century and a
94 failure to improve the processes by which clinical practice learns and responds will ultimately
95 lead to unnecessary morbidity and mortality.⁴

96

97 In this manuscript, we track the evolution of clinical management guidelines across three
98 coronaviridae pan/epidemics: SARS-CoV-1, MERS-CoV and SARS-CoV-2. We particularly

99 focus on whether the rigour of development of guidelines and inclusivity of vulnerable groups
100 has improved between these outbreaks and over the course of the COVID-19 pandemic. We
101 aim to identify the strengths and weaknesses of guidelines produced in these settings and to
102 evaluate whether lessons from previous outbreaks have been learnt. For a subset of guidelines
103 in the current SARS-CoV-2 pandemic we also examine how responsive these CMGs are in
104 incorporating new evidence from the latest clinical trials. In doing so we ask the bigger question
105 of how clinical management guidelines can be improved as health professionals continue to
106 manage large numbers of COVID-19 patients and for future pandemics.
107

108 Methods

109 This review is an update of a rapid review¹ and part of a wider project evaluating the availability,
110 quality and inclusivity of clinical management guidelines for high consequence infectious
111 diseases (HCID). The Preferred Reporting in Systematic Reviews and Meta-Analyses
112 (PRISMA) checklist was used to construct this review (Figure 1).⁵

113 Search strategy

114 In a previous review, we found that most CMGs were not published in peer-reviewed journals
115 and rarely indexed in the electronic databases.¹ We therefore focussed our efforts on extensive
116 hand-searches of the grey literature using a combination of systematic Google and Google
117 Scholar searches and by specifically searching Ministry of Health, national public health agency
118 institutions, World Health Organisation (WHO), Centres for Disease Control and other infectious
119 disease society websites with pre-defined keywords (supplement). This was complemented by
120 utilising the International Severe Acute Respiratory and Emerging Infection Consortium
121 (ISARIC)⁶ network to contact clinical networks in regions where limited numbers of CMGs where

122 initially identified. Finally, we searched reference lists of included CMGs. We aimed to identify a
123 globally representative sample of CMGs, focusing on international and national CMGs in this
124 review for feasibility and because these likely inform the development of locally developed
125 guidelines at a hospital/regional level. The full search strategy is shown in the Supplementary
126 Methods. The search was completed on the 6th June 2020.

127 Inclusion/exclusion criteria

128 COVID-19, SARS, and MERS CMGs that included recommendations intended to optimize
129 patient care were included.⁷ Guidelines that were substantially local policy documents or
130 focused primarily on infection control/diagnostics were therefore excluded. There were no
131 language restrictions.

132

133 Screening

134 Records identified from searches were independently screened, first by title and abstract,
135 followed by full text, by two reviewers. Individuals with knowledge of the language the CMG was
136 written in were used; where this was not possible translations were produced with Google
137 Translate. Any disagreements were resolved by a third reviewer.

138 Data extraction

139 We utilised a standardised form to extract data (supplement). Data was extracted by one
140 reviewer and checked by a second reviewer.

141 Quality assessment

142 The quality of each CMG was assessed using the Appraisal of Guidelines, Research and
143 Evaluation version II (AGREE-II).⁸ The tool consists of 23 questions (scored on a 7-point scale,
144 from 1 (strongly disagree) to 7 (strongly agree)) across six key domains (scope and purpose;
145 stakeholder involvement; rigour of development; clarity of presentation; applicability; editorial
146 independence). All CMGs were assessed using AGREE-II by two reviewers independently.
147 CMGs where there was significant discordance in the reviewers assessments were identified by
148 calculating Cohen's Kappa; a threshold of 0.4 was used to trigger further discussion between
149 reviewers to resolve major disagreements. We considered three measures of whether a CMG
150 was high quality: an overall weighted score ≥ 0.7 (threshold suggested by the AGREE-II
151 developers), weighted score ≥ 0.7 on domains 3 and 5 (rigour of development and applicability,
152 previously shown to be most predictive of overall score⁹) and reviewers' overall assessment of
153 whether they would recommend use of the CMG. Weighted scores were calculated according to
154 the formula presented the AGREE-II manual⁸ :
$$\frac{\text{Obtained score} - \text{Minimum possible score}}{\text{Maximum possible score} - \text{Minimum possible score}}$$

155 Responsiveness/Quality over time (subset analysis)

156 We tracked a subset of 11 COVID-19 CMGs (selected because they also featured in our earlier
157 rapid review ¹) over time to assess their responsiveness to key results from randomised clinical
158 trials (RCTs) for six treatments (hydroxychloroquine, convalescent plasma, lopinavir-ritonavir,
159 remdesivir, dexamethasone and tocilizumab). For each CMG in this subset, we also compared
160 the AGREE-II scores to those given to earlier versions at the beginning of the pandemic in our
161 previous review.

162 Patient and Public Involvement

163 Members of the public were invited to comment on the results and interpretation of our study via
164 a social media COVID research participation group. Two semi-structured focus groups,
165 facilitated by two authors, were held via a teleconference call. Participants worked with review
166 authors to comment on the methodology and inform the interpretation and presentation of
167 results.

168 Statistics

169 Statistical analysis was performed in the R language for statistical computing¹⁰ version 4.0.2
170 with the ggplot library used to produce graphics.¹¹

171

172 Results

173 In the main searches completed on 6th June 2020, we identified 47 CMGs (Figure 1). 37
174 covered clinical management of COVID-19, four of MERS and six of SARS. Most COVID-19
175 CMGs were developed by government agencies and published on the websites as standalone
176 documents or acquired via the ISARIC⁶ network. In contrast, SARS and MERS guidelines were
177 generally published in peer-reviewed journals. Although we attempted to ensure that there were
178 at least five national COVID-19 CMGs per continent, we found fewer guidelines produced in
179 Australasia (n=1), South America (n=3) and Africa (n=6), compared to North America (n=7),
180 Europe (n=12), and Asia (n=15). By the World Bank definition,¹² most guidelines were produced
181 in high (n=21) and upper middle (n=14), followed by lower middle (n=8) and low-income
182 countries (n=1). Three CMGs were produced by international agencies.¹³⁻¹⁵

183

184 Quality evaluation

185 Most CMGs were not high quality by any of the three objective measures we used. For
186 example, (27%) 10/37 of COVID-19 CMGs had an overall score of 0.7 or above compared to
187 2/4 (50%) MERS and 0/6 (0%) SARS. Only one guideline scored 0.7 or more for domains 3
188 (clarity of presentation) and 5 (rigour of development) (Korean Society of Infectious Disease
189 MERS-CoV guideline¹⁶); notably no COVID-19 guidelines met this standard. In total 25/47
190 CMGs were recommended for use by both reviewers though there were only six (two MERS-
191 CoV and four COVID-19) where both reviewers agreed no modification was desirable. The
192 highest score of these were COVID-19 CMGs developed by the Infectious Diseases Society of
193 America (IDSA),¹⁷ Surviving Sepsis Campaign,¹⁴ and a MERS CMG developed by the Korean
194 Society of Infectious Disease.¹⁶ These were notable for their clear expression of clinical
195 questions which were answered rigorously using a defined methodology and were presented to
196 a high standard.

197
198 Considering all included CMGs, quality was not equal across the domains of the AGREE-II tool
199 (Kruskall-Wallis $p < 0.001$) and there was a wide distribution of scores within domains (Figure 2).
200 Editorial independence' (median weighted score 0 interquartile range (IQR) 0-0.08) and rigour of
201 development (median weighted score 0.23 (IQR 0.13-0.35) were the lowest scoring domains.
202 The low scores for editorial independence were generally because there was no statement
203 about the role of the funding body and many lacked conflicts of interest declarations. Low
204 scores for rigour of development reflected the absence of a description of a systematic evidence
205 search methodology, a lack of explicit links to supporting evidence and unclear methods for
206 selecting key recommendations. CMGs scored better for the 'Clarity of Presentation' domain
207 (median weighted score 0.67, IQR (0.47-0.81)). There was weak evidence of a difference in the

208 overall scores of guidelines produced by academic societies vs public health agencies (median
209 4.5 (IQR 3.5-5.5) vs. median 3.8 (IQR 3.0-4.5), Wilcox $p=0.06$).

210

211 No improvement in quality over time

212 To evaluate whether the quality of CMGs improved over time, we appraised CMGs from three
213 coronaviridae outbreaks (SARS 2002-2004, MERS 2012 and COVID-19 2020). There was no
214 evidence that overall scores were different between these outbreaks (SARS median 0.47 (IQR
215 0.33-0.61), MERS median 0.54 (IQR 0.27-0.83), COVID-19 median 0.57 (IQR 0.50-0.71),
216 Kruskal-Wallis $p=0.35$). Notably there was also no evidence of improvement in any of the six
217 domains measured by the AGREE-II tool between the initial and updated COVID-19 guidelines
218 (Bonferroni adjusted paired Wilcoxon Rank Sum $p>0.1$ in all cases, Figure 2).

219 Inclusivity of CMGs

220 Many CMGs were not specific in their description of the target population. This was reflected in
221 the fact that only 34% (16/47) of all CMGs scored five or more in this AGREE-II question. Most
222 guidelines included general advice for the management of adults, pregnant women, and
223 children, but older and other high-risk groups patients (e.g. immunosuppressed) were notable
224 omissions from many guidelines (Table 1). There were however some examples where this was
225 done well for example in the WHO CMG which includes specific sections relating to the care of
226 older people and pregnant women with COVID-19 as well as guidance on palliative care.

227

228 Supportive Care Recommendations

229 Nearly all CMGs gave recommendations for aspects of basic supportive care though there was
230 generally little or no supporting literature cited. Most suggested target saturations and methods
231 of oxygen delivery in hypoxic patients, but there were often no links to or discussion of relevant
232 studies. For example, the WHO CMG notes that there is no evidence based guidance for the
233 use of high flow nasal cannula (HFNC) in this setting and recommends that selected patients
234 with COVID-19 and mild acute respiratory distress syndrome (ARDS) be considered for a
235 therapeutic trial of Non-invasive ventilation (NIV).¹³ No literature is provided to support this
236 recommendation and the criteria for selecting patients for such a trial are unclear. Similarly the
237 Surviving Sepsis COVID-19 CMG recommends the use of HFNC over NIV but notes that the
238 quality of evidence is weak.¹⁴ As a further example, (62%) 23/37 COVID-19 guidelines
239 recommended the use of antimicrobial therapy if bacterial superinfection was clinically
240 suspected. However most did not give guidance as to how this decision should be made nor
241 give clear criteria for stopping (table 2). Three guidelines recommended the use of procalcitonin
242 to guide antimicrobial use though did not provide specific thresholds.¹⁸⁻²⁰ Some stratified
243 recommendations for initiating antibiotics by severity of presentation.²¹⁻²³

244 Recommendations prior to the availability of high-quality evidence

245 CMGs varied markedly in their approach to uncertainty of therapeutic efficacy. Some noted the
246 presence of ongoing clinical trials but made no comment on whether an agent should be used
247 whilst others explicitly stated that no recommendation either way could be made. There were
248 several instances where CMGs recommended that where such uncertainty existed, individual
249 case-by-case decisions should be made based on clinical judgement (e.g. COREB for
250 remdesivir/hydroxychloroquine/lopinavir-ritonavir²⁴ and the Korean Society of Infectious
251 Diseases for Intravenous (IV) immunoglobulin²⁵). Others (e.g. US CDC,²⁶ IDSA¹⁷ and WHO¹³)

252 stated that where there was a lack of evidence, agents should only be used in the context of a
253 clinical trial (Figure 3).

254

255 Responsiveness to emerging evidence

256 We followed a group of COVID-19 guidelines and tracked their recommendations on six
257 treatments between January and November 2020 (Figure 3). Of the COVID-19 CMGs, 6/11
258 (55%) changed their guidance on the use of Dexamethasone in response to the results of the
259 Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial and the Embedded, Multi-
260 factorial, Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP) trial.^{17 20 23}
261 ²⁶⁻³⁷ Four CMGs initially recommended the use of lopinavir/ritonavir and/or hydroxychloroquine,
262 and all except one, a Russian CMG which noted anecdotal success with its use and
263 recommended use in moderate cases²⁰, recommended against its use after the publication of
264 the RECOVERY/SOLIDARITY trials,^{36 38} In the case of Remdesivir, 5/11 (45%) CMGs
265 recommended its use prior to the publication of the results of the Adaptive COVID-19 Treatment
266 Trial (ACTT-1).³⁹ A similar theme was apparent in the SARS/MERS guidelines where 4/10
267 (40%) recommended the use of corticosteroids either absolutely or on a case-by-case basis,
268 despite a lack of evidence.⁴⁰

269 Stakeholder engagement

270 In our AGREE-II evaluations, CMGs were consistently poorly rated for their involvement of
271 patient groups in their development (median score 0, (IQR 0-0)). Whilst our patient group
272 acknowledged the need for speed, they unanimously and strongly believed that public
273 involvement in the production of CMGs for COVID-19 would have been desirable to ensure that
274 the patient perspective is incorporated. For example, whilst specialists are understandably
275 focused on acute and critical care, the group felt that patient involvement might have highlighted
276 the need for better integration with primary care and the potential utility of ambulatory monitoring
277 (e.g. pulse oximetry). Involving patients early in a pandemic is understandably challenging,
278 nevertheless, development of a pre-identified group that can quickly be available when needed
279 in future was suggested. The patient group were of the opinion that stakeholder involvement,
280 rigour of development and editorial independence (the worst performing domains in our
281 AGREE-II evaluation) were important and that a compromise in their quality was not acceptable
282 despite the mitigating consideration of a pandemic setting. All participants agreed that making
283 CMGs more accessible to a lay audience is something they would value. A few individuals
284 proposed the use of guideline summaries written in plain English, or in the form of infographics
285 and videos. Participants felt that this would better enable patient centred care by facilitating
286 informed discussions with health care professionals.

287 Discussion

288 This review and responsiveness evaluation of CMGs in MERS, SARS and COVID-19
289 demonstrates that, as was the case earlier in the pandemic,¹ many CMGs have substantial
290 methodological flaws and there has been little or no improvement between outbreaks/within the
291 COVID-19 pandemic. The substantial heterogeneity observed in therapeutic recommendations

292 at the beginning of the pandemic did however narrow as reliable evidence from clinical trials
293 became available. The rationale for recommendations around supportive care was often unclear
294 and the quality of evidence used to inform these was notably poor. Many CMGs recommended
295 treatments despite them being non-evidence based or even having demonstrated futility.
296 Despite a body of literature now available highlighting atypical presentations of COVID-19,
297 particularly in elderly patients (e.g. less fever, more delirium, falls and diarrhoea⁴¹), and risk of
298 more severe diseases, most guidelines did not provide specific advice for management of this
299 patient group.^{19 21 22 42-45}

300

301 *Unanswered questions and future research*

302 Our review highlighted that recommendations on supportive care made by CMGs are often
303 underpinned by limited and/or low-quality evidence. Where CMGs did conduct a systematic
304 evidence review, this was usually primarily focussed on antiviral or immunomodulatory therapy.
305 General aspects of supportive care (e.g. timing of intubation vs. a trial of NIV, target oxygen
306 saturations, whether to give antibiotics, fluid balance decisions and thromboprophylaxis
307 dose/agent/post-discharge regimen) are applicable to all viral infectious diseases with pandemic
308 potential and especially important for emerging infections when the evidence base for pathogen
309 specific therapy is limited. These issues should be addressed in living syndromic systematic
310 reviews which would highlight knowledge gaps to be addressed in clinical trials and aid the rapid
311 production of rigorous pathogen specific guidelines. Significant investment in the evidence base
312 surrounding basic supportive care would likely yield great rewards in future and be globally
313 applicable, especially given the relatively greater accessibility and lower cost of these
314 interventions. At the onset of outbreaks, guideline committees could then identify pathogen
315 specific clinical questions for which pragmatic RCTs could be established.

316

317 These results demonstrate the need for a better framework for the development of CMGs in
318 outbreak settings. CMGs can still be useful and developed in a rigorous manner even when the
319 quality and quantity of evidence available is minimal. Dissemination of expert opinion may be
320 useful where there is no better option but should be clearly signposted as such and the rationale
321 for recommendations needs to be clearly and transparently presented. We suggest that at least
322 the initial methodology used to produce CMGs is subjected to a more transparent review
323 process and ideally that these reviews should also be published. This is particularly pertinent
324 given that the quality of CMGs did not appear to improve over time, and updated versions use a
325 near identical format to the original. This need not slow their release which could initially be
326 noted as interim guidance having not yet undergone such review (in a similar manner to
327 preprints).

328
329 CMGs would benefit from incorporating succinct summaries, with decision making tools such as
330 flowcharts and algorithms to aid rapid decision making on the front line. Patient groups should
331 be involved in the development of CMGs from the beginning and lay summaries should be
332 produced to enable patients to take a proactive and informed role in their care. Whilst this is
333 more challenging in the initial phase of the pandemic, it would be feasible and desirable to have
334 a pool of lay volunteers on standby who could be recruited at short notice to provide input into
335 both guideline development and clinical research. As the COVID-19 pandemic has evolved, a
336 variety of different issues have emerged, including atypical COVID-19 presentations,⁴¹ post
337 COVID-19 syndrome⁴⁶ and difficulty accessing medical care during lockdowns. Continuous
338 engagement with all stakeholders would help to identify these issues and ensure that guidelines
339 are responsive to them.

340
341 We observed substantial variation in the way that CMGs approach uncertainty when making
342 recommendations on the basis of little and/or low-quality evidence. There are several examples

343 where guidelines either recommended an unproven agent for use in particular patient groups or
344 on a case-by-case basis. There is always a temptation for “compassionate use” of biologically
345 plausible agents for individual patients *in extremis* with no proven treatment option.⁴⁷ If however
346 all patients who were treated with steroids/hydroxychloroquine/remdesivir/convalescent plasma
347 had been randomised into trials from the beginning of the pandemic, we would have known
348 whether these agents are beneficial (or indeed harmful) much sooner and more patients could
349 have benefitted from these results. The success of pragmatic trials such as
350 SOLIDARITY/RECOVERY have demonstrated the feasibility of this even in pandemic settings.

351 ^{36 38}

352

353 **Strengths and weaknesses of the study**

354 The inclusion of CMGs from a wide range of countries and organisations over a period of time is
355 a strength of this study. This allowed us to evaluate the response of guideline committees to
356 new emerging evidence. Our review is skewed towards countries in higher income
357 classifications and we only identified one CMG from a low-income country (LIC).⁴⁸⁻⁵⁰ The
358 AGREE-II tool is not specifically designed to appraise infectious disease CMGs produced during
359 a pandemic, which may have caused us to underestimate the quality of some guidelines.

360

361 **Conclusions and policy implications**

362 In conclusion, the quality of guidelines has not improved over time and despite publication of
363 data from key clinical trials, some CMGs continue to recommend the use of agents found to be
364 ineffective in RCTs. Existing guideline development frameworks which have successfully
365 improved the quality of CMGs in general, have had minimal effect on those produced in

366 response to epidemics and pandemics. This highlights a need for a CMG development
367 framework for the production of timely, evidence based, resource conscious, locally adaptable
368 and inclusive CMGs in response to emerging outbreaks. Vulnerable groups and in particular
369 the elderly continue to be disproportionately overlooked and the relevant specialities (e.g.
370 geriatrics) are underrepresented in CMG development groups. Given that COVID-19 has had
371 such a profound impact on so many people's lives and that such a vast quantity of public money
372 has been spent, involvement of patients and the public in outbreak preparedness and response,
373 including in CMG development is an area that needs to be urgently improved and must not be
374 neglected in the future.

375

376

377 **Authors' Contributions**

378 SL, IR and VC wrote the first draft of the manuscript, with input from LS and AD. EH performed
379 the search strategy and executed the database search. SL performed the analysis of the
380 AGREE-II scores and SL and IR created the figures. PB, EC, MT, TE, KL, LM, IR, SL, AD, MM,
381 VC, and AVG screened the references, assisted with data and interpretation. KC provided
382 additional comments from a lay perspective and helped to draft sections relating to PPI. LS and
383 AD conceptualised the protocol and study. LS and PH provided overall supervision of the
384 project. All authors reviewed and approved the final content for publication.

385

386 The corresponding author attests that all listed authors meet the authorship criteria and that no
387 others meeting the criteria have been omitted.

388

389 **Funding**

390 This work was supported by Wellcome. The results presented have been obtained with the
391 financial support of the EU FP7 project PREPARE (602525). SL is an MRC Clinical Research
392 Training Fellow (MR/T001151/1).

393

394

395 **Competing interest**

396 None declared

397

398 **Ethical approval**

399 We sought the opinion of the University of Oxford ethics committee who opined our involvement
400 of a patient group constituted patient-public involvement and thus did not require ethical review.

401 **Data Sharing**

402 Raw AGREE-II scores have been deposited on FigShare

403 (<https://doi.org/10.6084/m9.figshare.13561991.v1>)

404

405 **Transparency statement**

406 The lead author affirms that the manuscript is an honest, accurate and transparent account of
407 the study being reported; no important aspects of the study have been omitted; any
408 discrepancies from the study as originally planned have been explained.

409

410 **Acknowledgements**

411 We would like to express our gratitude to the ISARIC network of Infectious disease
412 physicians/public health practitioners who were valuable in searching and providing clinical
413 management guidelines used in this review. Notably, the Ministry of Health Seychelles,
414 Christine Williams, Dr. Desmond Oppong at the Greater Accra Regional Hospital, Ghana and
415 Prof. Simon Anderson at the University of the West Indies. We thank our patient group for their

416 suggestions and feedback. We thank the ISARIC global coordinating center for their help and
417 support. Thanks to Sarah Dawson for providing advice regarding the formatting of the
418 references. The authors also thank Julian Higgins for his critical reading of the manuscript.

419

420

421 **List of abbreviations**

422 CMG- Clinical Management guidelines

423 SARS-CoV-1-Severe Acute Respiratory Syndrome Coronavirus-1

424 MERS-CoV- Middle East Respiratory Syndrome Coronavirus

425 COVID-19- Coronavirus Disease-19

426 SARS-CoV-2- Severe Acute Respiratory Syndrome Coronavirus-2

427 PREPARE-Platform for European Preparedness Against (Re-)emerging Epidemics

428 PROSPERO- International Prospective Register of Systematic Reviews

429 AGREE-II - Appraisal of Guidelines for Research and Evaluation II

430 HCID- High Consequence Infectious Disease

431 ISARIC- International Severe Acute Respiratory and emerging Infection Consortium

432 IQR- Interquartile Range

433 NIV- Non-invasive ventilation

434 IV- Intravenous

435 RECOVERY- Randomised Evaluation of COVID-19 Therapy

436 CDC- Centers for Disease Control and Prevention

437 IDSA- Infectious Diseases Society of America

438 WHO- World Health Organisation

439 REMAP-CAP- Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-
440 Acquired Pneumonia

441 RCT- Randomised Control Trial

442 ACTT-1- Adaptive COVID-19 Treatment Trial

443 ARDS- Acute Respiratory Distress Syndrome

444

445

446

447 References

448

- 449 1. Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced
450 early in the covid-19 pandemic: rapid review. *BMJ* 2020;369:m1936. doi:
451 10.1136/bmj.m1936 [published Online First: 2020/05/28]
- 452 2. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with COVID-
453 19-related hospital death in the linked electronic health records of 17 million adult NHS
454 patients. *MedRxiv* 2020 doi: 10.1101/2020.05.06.20092999
- 455 3. Public Health England. Disparities in the risk and outcomes of COVID-19, 2020.
- 456 4. Global Preparedness Monitoring Board. A World at Risk- Annual report on global
457 preparedness for health emergencies: World Health Organization.
- 458 5. Moher D LA, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews
459 and meta-analyses: the PRISMA statement. *PLoS Med* 2009 doi: doi:
460 10.1371/journal.pmed.1000097
- 461 6. International Severe Acute Respiratory and Emerging Infection Consortium. International
462 Severe Acute Respiratory and emerging Infection Consortium 2020 [Available from:
463 <https://isaric.org/>.
- 464 7. Graham R MM, Wolman D, Greenfield S, Steinberg E. Clinical guidelines we can trust.
465 *National Academies Press* 2011;266 doi: DOI: 10.17226/13058
- 466 8. Brouwers MC KM, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II:
467 advancing guideline development, reporting and evaluation in health care. *Preventive
468 Medicine* 2010;51(5)
- 469 9. Hoffmann-Esser W, Siering U, Neugebauer EA, et al. Guideline appraisal with AGREE II:
470 Systematic review of the current evidence on how users handle the 2 overall
471 assessments. *PLoS One* 2017;12(3):e0174831. doi: 10.1371/journal.pone.0174831
472 [published Online First: 2017/03/31]
- 473 10. R Core Team. R: A language and environment for statistical computing, 2017.
- 474 11. Wickham H. ggplot2: Elegant Graphics for Data Analysis: Springer-Verlag New York 2016.
- 475 12. The World Bank. The World Bank 2021 [Available from: <https://www.worldbank.org/>.
- 476 13. World Health Organisation. Clinical Management of COVID-19 2020 [updated 27 May
477 2020]. Available from: [https://www.who.int/publications/i/item/clinical-management-of-
478 covid-19](https://www.who.int/publications/i/item/clinical-management-of-covid-19) [Accessed: 10 June 2020].
- 479 14. Alhazzani Waleed MH, Møller; Yaseen, M. Arabi; Mark, Loeb; Michelle Ng, Gong; Eddy,
480 Fan; Simon, Oczkowski; Mitchell, M. Levy; Lennie, Derde; Amy, Dzierba; Bin, Du;
481 Michael, Aboodi; Hannah, Wunsch; Maurizio, Cecconi; Younsuck, Koh; Daniel, S.
482 Chertow; Kathryn, Maitland; Fayez, Alshamsi; Emilie, Belley-Cote; Massimiliano, Greco;
483 Matthew, Laundry; Jill, S. Morgan; Jozef, Kesecioglu; Allison, McGeer; Leonard, Mermel;
484 Manoj, J. Mammen; Paul, E. Alexander; Amy, Arrington; John, E. Centofanti; Giuseppe,
485 Citerio; Bandar, Baw; Ziad, A. Memish; Naomi, Hammond; Frederick, G. Hayden; Laura,

- 486 Evans; Andrew, Rhodes. Surviving Sepsis Campaign: guidelines on the management of
487 critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Medicine*
488 2020;46:854-87. doi: 10.1007/s00134-020-06022-5
- 489 15. World Health Organisation. Clinical management of severe acute respiratory infection when
490 Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected 2019
491 [updated January 2019]. Available from:
492 https://www.who.int/csr/disease/coronavirus_infections/ipc-mers-cov/en/ [Accessed: 5
493 August 2020].
- 494 16. Yong Pil CJY, Song; Yu Bin, Seo; Jae Phil, Choi; Hyoung Shik, Shin; Hee Jung, Yoon; Jun
495 Yong, Choi; Tae Hyong, Kim; Young Hwa, Choi; Hong Bin, Kim; Ji Hyun, Yoon; Jacob,
496 Lee; Joong Sik, Eom; Joon Young, Song; Sang Oh, Lee; Won Sup, Oh; Hee Jin,
497 Cheong; Young Goo, Song; Jung Hyun, Choi; Woo Joo, Kim. Antiviral treatment
498 guidelines for middle east respiratory syndrome. *Infection and Chemotherapy*
499 2015;47:212-22. doi: 10.3947/ic.2015.47.3.212
- 500 17. Adarsh BR, L. Morgan; Amy Hirsch, Shumaker; Valery, Lavergne; Lindsey, Baden; Vincent
501 Chi-Chung, Cheng; Kathryn, M. Edwards; Rajesh, Gandhi; William, J. Muller; John, C.
502 O.; Shmuel, Shoham; M. Hassan Murad; Reem, A. Mustafa; Shahnaz, Sultan; Yngve,
503 Falck-Ytter. Infectious Diseases Society of America Guidelines on the Treatment and
504 Management of Patients with COVID-19 Version 1.0.3 2020 [updated 13 April 2020].
505 Available from: www.idsociety.org/COVID19guidelines. [Accessed 4 November 2020].
- 506 18. Ministry of Health Family Welfare Bangladesh. National Guidelines on Clinical Management
507 of Coronavirus Disease 2019 (Covid-19) Verison 4 2020 [updated 30 March 2020].
508 Available from: https://corona.gov.bd/documents/COVID_Guideline_V4.0..30.3.2020.pdf
509 [Accessed: 2 June 2020].
- 510 19. Government of Pakistan Ministry of National Health Services. Clinical Management
511 Guidelines for COVID-19 Infections Version 02 2020 [updated 1 June 2020]. Available
512 from: [https://www.nih.org.pk/wp-content/uploads/2020/06/20200106-Clinical-
513 Management-Guidelines-for-COVID-19-infection-v2.pdf](https://www.nih.org.pk/wp-content/uploads/2020/06/20200106-Clinical-Management-Guidelines-for-COVID-19-infection-v2.pdf) [Accessed 27 July 2020].
- 514 20. Министерство здравоохранения Российской. ВРЕМЕННЫЕ
515 МЕТОДИЧЕСКИЕ РЕКОМЕНДАЦИИ ПРОФИЛАКТИКА, ДИАГНОСТИКА И ЛЕЧЕНИЕ
516 НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИ (Covid-19) Версия 7 (03.06.2020) 2020
517 [updated 3 June 2020]. Available from: [https://static-
518 0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9
519 CR_COVID-19_v7.pdf](https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf) [Accessed: 27 July 2020].
- 520 21. Nepal Medical Council. Interim Clinical Guidance for Care of Patients with Covid-19 in
521 Healthcare Settings 2020 [updated 3 April 2020]. Available from:
522 [https://nmc.org.np/files/4/NMC%20COVID-
523 19%20Interim%20Clinical%20Guideline%20for%20care%203%20April.pdf](https://nmc.org.np/files/4/NMC%20COVID-19%20Interim%20Clinical%20Guideline%20for%20care%203%20April.pdf) [Accessed:
524 15 June 2020].
- 525 22. Tave F S; Michel R; Saha K B; Noel M; Hassanein M; Fayon M; Pugazhendhi S; Michel J;
526 Pool B; Comarmond d L; Chetty A. Seychelles Clinical Guidelines for the Management
527 of Severe Acute Respiratory Infection (SARI) in Patients with Confirmed COVID-19
528 Disease Version 1 2020 [updated 20 March 2020].
- 529 23. Ministry of Health Welfare Taiwan Centers for Disease Control. Interim Guidelines for
530 Clinical Management of SARS-CoV-2 Infection 5th Edition 2020 [updated 26 March
531 2020]. Available from: [https://www.cdc.gov.tw/Uploads/d812c836-4956-4d4b-8775-
532 a50e58e300b8.pdf](https://www.cdc.gov.tw/Uploads/d812c836-4956-4d4b-8775-a50e58e300b8.pdf) [Accessed: 10 June 2020].
- 533 24. Haut Conseil de la Sante Publique. Avis relatif aux recommandations thérapeutiques dans
534 la prise en charge du COVID-19 (complémentaire à l'avis du 5 mars 2020) 2020 [updated
535 23 March 2020]. Available from:

- 536 https://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20200323_coronsarscov
537 [recomthrap.pdf](#) [Accessed: 22 June 2020].
- 538 25. Korean Society of Infectious Diseases. 신종코로나바이러스 검사에 대한 대한감염학회
539 권고안 2020 [updated 11 February 2020]. Available from:
540 <http://www.ksid.or.kr/eng/main/main.html> [22 July 2020].
- 541 26. Centers for Disease Control Prevention. Interim Clinical Guidance for Management of
542 Patients with Confirmed Coronavirus Disease (COVID-19) as of May 29, 2020 2020
543 [updated 29 May 2020]. Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html)
544 [ncov/hcp/clinical-guidance-management-patients.html](#) [Accessed: 1 April 2020].
- 545 27. Adarsh BR, L. Morgan; Amy Hirsch, Shumaker; Valery, Lavergne; Lindsey, Baden; Vincent
546 Chi-Chung, Cheng; Kathryn, M. Edwards; Rajesh, Gandhi; Jason, Gallagher; William, J.
547 Muller; John, C. O.; Shmuel, Shoham; M. Hassan Murad; Reem, A. Mustafa; Shahnaz,
548 Sultan; Yngve, Falck-Ytter. Infectious Diseases Society of America Guidelines on the
549 Treatment and Management of Patients with COVID-19 Verion 3.3 2020 [updated 25
550 June 2020]. Available from: www.idsociety.org/COVID19guidelines [Accessed: 4
551 November 2020].
- 552 28. Robert Koch Institute. Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit
553 COVID-19 Stand: März 2020 2020 [updated March 2020]. Available from:
554 [https://www.bmj.com/lookup/google-](https://www.bmj.com/lookup/google-scholar?link_type=googlescholar&gs_type=article&q_txt=.%2BDiagnosis%2Band%2Btreatment%2Bof%2Bpatients%2Bwith%2BCOVID-19.Robert%2BKoch%2Binstitute%2C%2020)
555 [scholar?link_type=googlescholar&gs_type=article&q_txt=.%2BDiagnosis%2Band%2Btreatment%2Bof](#)
556 [%2Bpatients%2Bwith%2BCOVID-19.Robert%2BKoch%2Binstitute%2C%2020](#). [Accessed: 6 June 2020].
- 557 29. Robert Koch Institute. Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit
558 COVID-19 Stand: 09.10.2020 2020 [updated 9 October 2020]. Available from:
559 www.stakob.rki.de
560 [https://www.rki.de/DE/Content/Kommissionen/Stakob/Stellungnahmen/Stellungnahme-](https://www.rki.de/DE/Content/Kommissionen/Stakob/Stellungnahmen/Stellungnahme-Covid-19_Therapie_Diagnose.pdf?__blob=publicationFile)
561 [Covid-19_Therapie_Diagnose.pdf?__blob=publicationFile](#) [Accessed: 15 October
562 2020].
- 563 30. Министерство здравоохранения Российской Федерации. ВРЕМЕННЫЕ МЕТОДИЧЕСКИЕ
564 РЕКОМЕНДАЦИИ ПРОФИЛАКТИКА, ДИАГНОСТИКА И ЛЕЧЕНИЕ НОВОЙ
565 КОРОНАВИРУСНОЙ ИНФЕКЦИИ (COVID-19) Версия 8 (03.09.2020) 2020 [updated 3
566 September 2020]. Available from: [https://static-](https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf?utm_source=yxnews&utm_medium=desktop)
567 [0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVI](#)
568 [D-19_v8.pdf?utm_source=yxnews&utm_medium=desktop](#) [Accessed: 1 October 2020].
- 569 31. Centers for Disease Control Prevention. Interim Clinical Guidance for Management of
570 Patients with Confirmed Coronavirus Disease (COVID-19) as of September 10, 2020
571 2020 [updated 10 September 2020]. Available from:
572 [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html)
573 [patients.html](#) [10 September 2020].
- 574 32. 衛生福利部疾病管制署. 新型冠狀病毒 (SARS-CoV-2) 感染臨床處置暫行指引 2020
575 [updated 17 August 2020]. Available from: <https://www.cdc.gov.tw/> [Accessed: 1
576 September 2020].
- 577 33. Darmon M ME, Morawiec E, Schnell D, Maury E, Constantin M J, Montravers P et al.
578 Recommandations d'experts portant sur la prise en charge en réanimation des patients
579 infectés à SARS-CoV2 Version 5 du 07/11/2020 2020 [updated 7 November 2020].
580 Available from: [https://sfar.org/download/recommandations-dexperts-portant-sur-la-](https://sfar.org/download/recommandations-dexperts-portant-sur-la-prise-en-charge-en-reanimation-des-patients-en-période-depidemie-a-sars-cov2/)
581 [prise-en-charge-en-reanimation-des-patients-en-période-depidemie-a-sars-cov2/](#)
582 [Accessed: 17 November 2020].
- 583 34. Coreb Mission Nationale. Recommandations d'experts portant sur la prise en charge en
584 réanimation des patients en période d'épidémie à SARS-CoV2 Version 4 2020 [updated

- 585 7 April 2020. Available from: [https://sfar.org/recommandations-dexperts-portant-sur-la-](https://sfar.org/recommandations-dexperts-portant-sur-la-prise-en-charge-en-reanimation-des-patients-en-periode-depidemie-a-sars-cov2/)
586 [prise-en-charge-en-reanimation-des-patients-en-periode-depidemie-a-sars-cov2/](https://sfar.org/recommandations-dexperts-portant-sur-la-prise-en-charge-en-reanimation-des-patients-en-periode-depidemie-a-sars-cov2/)
587 [Accessed: 10 July 2020].
- 588 35. Darmon MB, Lila; Morawiec, Elise; Maury, Eric; Constantin, Jean-Michel; Montravers,
589 Philippe; Zahar, Jean-Ralph; Lucet, Jean-Christophe; Guery, Benoit; Bessis, Simon;
590 Saidani, Nadia; Desmettre, Thibault; Dumas, Florence;. Recommendations d'experts
591 portant sur la prise en charge en réanimation des patients en période d'épidémie à
592 SARS-CoV2 Version 2 du 10/03/2020 2020 [updated 10 March 2020]. Available from:
593 [https://www.srlf.org/wp-content/uploads/2020/03/Recommandations-dexperts-COVID-](https://www.srlf.org/wp-content/uploads/2020/03/Recommandations-dexperts-COVID-19-10-Mars-2020.pdf)
594 [19-10-Mars-2020.pdf](https://www.srlf.org/wp-content/uploads/2020/03/Recommandations-dexperts-COVID-19-10-Mars-2020.pdf) [Accessed: 16 March 2020].
- 595 36. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-
596 19 — Preliminary Report. *The New England Journal of Medicine* 2020 doi: DOI:
597 10.1056/NEJMoa2021436
- 598 37. The Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on
599 Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP
600 COVID-19 Corticosteroid Domain Randomized Clinical Trial. *JAMA* 2020;324(13):1317-
601 29. doi: doi:10.1001/jama.2020.17022
- 602 38. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO
603 Solidarity Trial Results. *New England Journal of Medicine* 2020 doi:
604 10.1056/NEJMoa2023184
- 605 39. Beigel H J TMK, Dodd E Lori et al., for the ACTT-1 study Group Members. Remdesivir for
606 the Treatment of Covid-19 — Final Report. *New England Journal of Medicine*
607 2020;383:1813-26. doi: DOI: 10.1056/NEJMoa2007764
- 608 40. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS*
609 *Med* 2006;3(9):e343. doi: 10.1371/journal.pmed.0030343 [published Online First:
610 2006/09/14]
- 611 41. Kerr AD, Stacpoole SR. Coronavirus in the elderly: a late lockdown UK cohort. *Clin Med*
612 *(Lond)* 2020;20(6):e222-e28. doi: 10.7861/clinmed.2020-0423 [published Online First:
613 2020/09/12]
- 614 42. Ministry of Health Cuba. Infecciones por coronavirus – COVID-19 2020 [Available from:
615 <https://temas.sld.cu/coronavirus/covid-19/> [Accessed: 5 June 2020].
- 616 43. Ghana Ministry of Health. Provisional Standard Treatment Guidelines for Novel Coronavirus
617 Infection COVID - 19 Guidelines for Ghana Version 1.0 2020 [Available from:
618 <https://www.moh.gov.gh/wp-content/uploads/2016/02/COVID-19-STG-JUNE-2020-1.pdf>
619 [Accessed: 20 June 2020].
- 620 44. Pakistan Chest Society. COVID-19 Management Guidelines 2020 2020 [updated 28 March
621 2020]. Available from: [http://www.pakistanchestociety.pk/wp-](http://www.pakistanchestociety.pk/wp-content/uploads/2020/03/COVID-19-Management-guideline-PCS-28-March.pdf)
622 [content/uploads/2020/03/COVID-19-Management-guideline-PCS-28-March.pdf](http://www.pakistanchestociety.pk/wp-content/uploads/2020/03/COVID-19-Management-guideline-PCS-28-March.pdf)
623 [Accessed: 27 August 2020].
- 624 45. Department of Health Republic of South Africa. Clinical management of suspected or
625 confirmed COVID-19 disease Version 3 2020 [updated 27 March 2020]. Available from:
626 [https://www.nicd.ac.za/wp-content/uploads/2020/03/Clinical-Management-of-COVID-19-](https://www.nicd.ac.za/wp-content/uploads/2020/03/Clinical-Management-of-COVID-19-disease-Version-3_27March2020.pdf)
627 [disease_Version-3_27March2020.pdf](https://www.nicd.ac.za/wp-content/uploads/2020/03/Clinical-Management-of-COVID-19-disease-Version-3_27March2020.pdf) [Accessed: 28 June 2020].
- 628 46. National Health Services. Post-COVID Syndrome (Long COVID) 2020 [Available from:
629 <https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/>.
- 630 47. Rojek AM, Martin GE, Horby PW. Compassionate drug (mis)use during pandemics: lessons
631 for COVID-19 from 2009. *BMC Med* 2020;18(1):265. doi: 10.1186/s12916-020-01732-5
632 [published Online First: 2020/08/23]
- 633 48. Ministerio Da Saude. Suspeito de COVID-19 2020 [updated March 2020].

- 634 49. Ministério da Saúde. Orientações Para Manejo De Pacientes Com Covid-19 2020
635 [Available from: [https://portal.arquivos.saude.gov.br/images/pdf/2020/June/18/Covid19-](https://portal.arquivos.saude.gov.br/images/pdf/2020/June/18/Covid19-Orientac-o-esManejoPacientes.pdf)
636 [Orientac--o--esManejoPacientes.pdf](https://portal.arquivos.saude.gov.br/images/pdf/2020/June/18/Covid19-Orientac-o-esManejoPacientes.pdf) [Accessed: 1 July 2020].
- 637 50. Ministério Da Saúde. Fluxograma de Pacientes com Suspeita de Covid-19 nos Serviços
638 ambulatoriais (Triagem e Consultas Externas) 2020 [Available from:
639 [http://www.misau.gov.mz/index.php/normas-procedimentos-e-](http://www.misau.gov.mz/index.php/normas-procedimentos-e-fluxos?download=239:fluxogramas-e-protocolos)
640 [fluxos?download=239:fluxogramas-e-protocolos](http://www.misau.gov.mz/index.php/normas-procedimentos-e-fluxos?download=239:fluxogramas-e-protocolos) [Accessed: 24 July 2020].
- 641 51. European Respiratory Society. COVID-19: Guidelines and recommendations directory 2020
642 [Available from: [https://www.ersnet.org/covid-19-guidelines-and-recommendations-](https://www.ersnet.org/covid-19-guidelines-and-recommendations-directory)
643 [directory](https://www.ersnet.org/covid-19-guidelines-and-recommendations-directory).
- 644 52. Ministerio de Salud Argentina. Recomendaciones Para El Abordaje Terapeutico Version 2
645 2020 [updated 29 May 2020]. Available from: <https://www.argentina.gob.ar/salud>
646 [Accessed: 1 June 2020].
- 647 53. National Covid-Clinical Evidence Taskforce. Australian Guideline for the Clinical Care of
648 People with COVID-19 2020 [Available from: <https://covid19evidence.net.au/>
649 [Accessed:20 July 2020].
- 650 54. Ministry of Public Health. Directives Et Procedures Operationnelles Standards Pour La
651 Preparation Et La Reponse Au Covid-19 Au Cameroun 2020 [updated April 2020].
- 652 55. Ministry of Health Cuba. Infecciones por coronavirus – SARS [Available from:
653 <https://temas.sld.cu/coronavirus/sars-cov/> [Accessed: 5 June 2020].
- 654 56. Ministry of Health Cuba. Infecciones por coronavirus – MERS [Available from:
655 <https://temas.sld.cu/coronavirus/mers/> [Accessed: 5 June 2020].
- 656 57. National Institute for Research in Reproductive Health Indian Council of Medical Research.
657 Guidance for Management of Pregnant Women in COVID-19 Pandemic 2020 [Available
658 from: <http://www.nirrh.res.in/> [Accessed: 14 June 2020].
- 659 58. Stefan K, Janssens U, Welte T, Weber-Carstens S, Marx G , Karagiannidis C,. S1-
660 Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 Version
661 1 2020 [updated March 2020]; cited 123 123]. Available from:
662 <https://link.springer.com/article/10.1007/s00063-020-00674-3> [Accessed on 2 November
663 2020]46.
- 664 59. Ministry of Health Family Welfare India. Revised Guidelines on Clinical Management of
665 COVID – 19 2020 [updated 31 March 2020]. Available from:
666 [https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1](https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf)
667 [931032020.pdf](https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf) [Accessed: 2 June 2020].
- 668 60. Ministero della Salute. Gestione clinica dell ' infezione respiratoria acuta grave nei casi di
669 sospetta infezione da nuovo coronavirus (nCoV) 2020 [updated 12 January 2020].
670 Available from: http://www.salute.gov.it/imgs/C_17_pagineAree_5373_5_file.pdf
671 [Accessed: 24 July 2020].
- 672 61. Jamaica Ministry of Health and Wellness. Guideline for the management of Pregnancy
673 during the COVID-19 Pandemic 2020 [updated 25 March 2020]. Available from:
674 <https://www.moh.gov.jm/covid-19-resources-and-protocols/> [17 August 2020].
- 675 62. Jamaica Ministry of Health and Wellness. Covid-19 Preparedness and Response Plan for
676 Outbreak Control Clinical Management of Severe Acute Respiratory Infection When
677 Novel Coronavirus Covid-19 Infection Is Suspected Version 2 2020 [updated March
678 2020]. Available from: www.moh.gov.jm [https://www.moh.gov.jm/wp-](https://www.moh.gov.jm/wp-content/uploads/2020/04/2019nCoV-COVID-19-Clinical-Management-Guidelines-V2.pdf)
679 [content/uploads/2020/04/2019nCoV-COVID-19-Clinical-Management-Guidelines-V2.pdf](https://www.moh.gov.jm/wp-content/uploads/2020/04/2019nCoV-COVID-19-Clinical-Management-Guidelines-V2.pdf)
680 [Accessed: 17 August 2020].
- 681 63. 厚生労働省. 新型コロナウイルス感染症 Covid-19 V2 2020 [updated 18 May 2020].
682 Available from: <https://www.mhlw.go.jp/index.html> [Accessed: 27 July 2020].

- 683 64. 厚生労働省. 新型コロナウイルス感染症 (COVID-19) 診療の手引き_V3 2020 [updated 3
684 September 2020]. Available from: <https://www.mhlw.go.jp/content/000670444.pdf>
685 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00111.html [Accessed:
686 9 September 2020].
- 687 65. Chicamba Valeria LS, ; Nhamtubo Carmita, et al. Orientações para a Abordagem e
688 Tratamento do doente Pediátrico na UCIP do Hospital Central Maputo com COVID-19
689 2020 [
- 690 66. Nigeria Centre for Disease Control. National Interim Guidelines for Clinical Management of
691 COVID-19 Version 1 2020 [updated 14 March 2020]. Available from:
692 https://ncdc.gov.ng/themes/common/docs/protocols/177_1584210847.pdf [Accessed:
693 27 June 2020].
- 694 67. National Committee for Management of Covid-United Arab Emirates. National Guidelines for
695 Clinical Management and Treatment of COVID-19 Version 2 2020 [updated 3 April
696 2020]. Available from:
697 <https://www.dha.gov.ae/en/HealthRegulation/Documents/COVID%20National%20Guidelines%20FINAL%2018%20March.pdf> [Accessed: 20 May 2020].
- 698 68. National Health Service. Clinical management of persons admitted to hospital with
700 suspected COVID-19 infection Version 1 2020 [updated 19 March 2020]. Available from:
701 [https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/clinical-
702 management-of-persons-admitted-to-hospital-v1-19-march-2020.pdf](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/clinical-management-of-persons-admitted-to-hospital-v1-19-march-2020.pdf) [Accessed: 24
703 August 2020].
- 704 69. Maria Laura VC, Siroti; Guillermo, Montiel; Ada, Toledo; Carlos, Franceschini; Alejandro.
705 Martinez, Fraga; Leslie. Vargas, Ramirez; Jose Luis, Carillo; Martha. Torres, Fraga.
706 Recomendaciones para el Manejo No Invasivo e Invasivo de la Insuficiencia
707 Respiratoria Hipoxémica de Novo Covid--19. 2020 [Available from:
708 [https://www.aamr.org.ar/secciones/coronavirus/recomendaciones_soporte_ventilatorio
709 covid.pdf](https://www.aamr.org.ar/secciones/coronavirus/recomendaciones_soporte_ventilatorio_covid.pdf) [23 July 2020].
- 710 70. World Health Organisation. Clinical management of severe acute respiratory infection 2020
711 [updated March 2020]. Available from: [https://www.who.int/docs/default-
712 source/coronaviruse/clinical-management-of-novel-cov.pdf](https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf) [Accessed: 1 April 2020].
- 713 71. The Korean Society of Pediatric Infection Diseases. COVID-19 Guidelines: Pediatric Care
714 2020 [updated 20 March 2020]. 44]. Available from:
715 <http://www.ksid.or.kr/eng/main/main.html> [Accessed: 21 July 2020].
- 716 72. Korean Society for Infectious Diseases Korean Society for Antibacterial Therapy Korean
717 Society for Pediatric Infections Korean Society for Tuberculosis; Respiratory System.
718 코로나 19 (COVID-19) 약물 치료에 관한 전문가 권고안 (version 1.1) 2020 [updated 25
719 February 2020]. Available from: <http://www.ksid.or.kr/eng/main/main.html> [Accessed:
720 22 July 2020].
- 721 73. 이무식. 시론 지역사회와 함께 하는 코로나 19 (Covid-19) 극복 V 1.1 2020 [updated 1 March
722 2020]. Available from: <http://www.ksid.or.kr/eng/main/main.html> [Accessed: 1 June
723 2020].
- 724 74. Lim S W ARS, Read C R, on behalf of the SARS guidelines committee of the British
725 Thoracic Society,. Hospital management of adults with severe acute respiratory
726 syndrome (SARS) if SARS re-emerges - updated 10 February 2004. *Journal of Infection*
727 2004;49:1-7. doi: 10.1016/j.jinf.2004.04.001
- 728 75. National Health Commission of the People's Republic of China.
729 中东呼吸综合征病例诊疗方案 (2015年版) 2015 [updated 6 June 2015]. Available from:
730 <http://en.nhc.gov.cn/> [Accessed: 27 July 2020].

- 731 76. National Health Commission of the People's Republic of China.
732 传染性非典型肺炎 (Sars) 诊疗方案 (2004版) 2005 [updated 25 May 2005]. Available
733 from: <http://en.nhc.gov.cn/> [Accessed: 27 July 2020].
- 734 77. National Health Commission of the People's Republic of China. 新型冠状病毒肺炎诊疗方案
735 (试行第八版) 2020 [updated 19 August 2020]. Available from: <http://en.nhc.gov.cn/>
736 [Accessed: 17 September 2020].
- 737 78. Chinese Medical Association CAoCM. Consensus of the management of severe acute
738 respiratory syndrome. *Zhonghua yi xue za zhi* 2003;83:1731-52.
- 739 79. De La Famille Et Des Personnes Handicapees Ministere De La Sante. Conduite à tenir pour
740 la prise en charge des personnes présentant un syndrome ou une 2004 [updated 06
741 April 2004]. Available from: www.sante.gouv.fr [http://umvf.omsk-
742 osma.ru/infectiologie/www.infectiologie.com/site/medias/alertes/sars/protoc_060404.pdf](http://umvf.omsk-osma.ru/infectiologie/www.infectiologie.com/site/medias/alertes/sars/protoc_060404.pdf)
743 [Accessed: 22 June 2020].
- 744 80. Maxwell C MA, Tai KF, Seimer A,. SOGC Clinical Practice Guideline. Management
745 guidelines for obstetric patients and neonates born to mothers with suspected or
746 probable severe acute respiratory syndrome (SARS). No. 225, April 2009. *International*
747 *journal of gynaecology and obstetrics: the official organ of the International Federation of*
748 *Gynaecology and Obstetrics* 2009;107:82-86. doi: 10.1016/j.ijgo.2009.05.006
- 749 81. National Health Commission. Diagnosis and Treatment Protocol for Novel Coronavirus
750 Pneumonia (Trial Version 7). *Chinese Medical Journal* 2020;133 doi:
751 10.1097/CM9.0000000000000819
- 752 82. Ministerio De Sanidad. Documento técnico Manejo clínico de pacientes con enfermedad por
753 el nuevo coronavirus (COVID-19) 2020 [updated 3 March 2020]. Available from:
754 [https://www.seipweb.es/wp-content/uploads/2020/03/Protocolo_manejo_clinico_COVID-
755 19.pdf](https://www.seipweb.es/wp-content/uploads/2020/03/Protocolo_manejo_clinico_COVID-19.pdf) [Accessed: 10 March 2020].
- 756 83. Ministerio de Sanidad. Manejo clínico del COVID-19: unidades de cuidados intensivos 2020
757 [updated 18 June 2020]. Available from: <https://www.mscbs.gob.es/en/home.htm>
758 [Accessed: 25 June 2020].
- 759 84. Rijksinstituut voor Volksgezondheid en Milieu. Medicamenteuze behandeling voor patiënten
760 met COVID-19 (infectie met SARS-CoV-2) 2020 [updated 13 August 2020]
761 Available from: <https://swab.nl/nl/covid-19> [Accessed: 9 September 2020].
- 762 85. Società Italiana di Malattie Infettive e Tropicali. Linee Guida Sulla Gestione Terapeutica e di
763 Supporto per Pazienti con Infezione da Coronavirus COVID-19 2020 [updated March
764 2020]. Available from: [http://www.fvcalabria.unicz.it/COVID-19/LINEE-GUIDA/linee-
765 guida-SIMIT-marzo-2020.pdf](http://www.fvcalabria.unicz.it/COVID-19/LINEE-GUIDA/linee-guida-SIMIT-marzo-2020.pdf) [1 April 2020].
- 766 86. Vollaard AE, Pauline; Gieling, Emilie; Boer de, Mark; Snijder, Erik; Dissel Van, Jaap.
767 Medicamenteuze behandelopties voor opgenomen patiënten met COVID-19 2020
768 [updated 3 March 2020]. Available from: <https://www.rivm.nl/> [Accessed: 1 April 2020].
- 769 87. Ministerio De Sanidad. Documento técnico Manejo clínico del COVID-19: atención
770 hospitalaria 2020 [updated 18 June 2020]. Available from:
771 [https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/docum
772 entos/Protocolo_manejo_clinico_ah_COVID-19.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Protocolo_manejo_clinico_ah_COVID-19.pdf) [25 June 2020].
- 773 88. British Thoracic Society and Scottish Intercollegiate Guidelines Network. SIGN158 British
774 guideline on the management of asthma. A national clinical guideline. 2003 [updated
775 July 2019. Available from: [https://www.brit-thoracic.org.uk/quality-
776 improvement/guidelines/asthma2020](https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma2020).
- 777 89. Società Italiana Malattie Infettive e Tropicali Sezione Regione Lazio. Gruppo di Lavoro
778 COVID-19-SIMIT Lazio Comitato di Redazione 2020 [updated 5 May 2020]. Available
779 from: <https://www.simi.it/> [Accessed: 10 May 2020].

780 90. Ministerio De Sandidad. Documento técnico Manejo de la mujer embarazada y el recién
781 nacido con COVID-19 2020 [updated 13 May 2020]. Available from:
782 <https://www.mscbs.gob.es/en/home.htm> [Accessed: 1 June 2020].
783




Figure 1: PRISMA diagram




Figure 2: Weighted scores for the six domains of the AGREE-II tool for the four groups of CMGs included. Dagens et al¹ refers to CMGs published in the early part of the COVID-19 pandemic. The boxplots show median and interquartile range (IQR) with the upper/lower whiskers showing the position of 1.5 * IQR; individual datapoints are represented by black dots.




Figure 3: Adoption of evidence from clinical trials by CMGs over time. Intersecting vertical lines show the publication of key clinical trials either as peer-reviewed articles/pre-prints or press-releases. Dots show the publication of CMGs by bodies shown on the y axis coloured according to the recommendation made.